Get the Stockscreener App
4.51
3.68%
0.16
After Hours:
4.57
0.06
+1.33%
Artelo Biosciences Inc stock is traded at $4.51, with a volume of 233.32K.
It is up +3.68% in the last 24 hours and down -52.43% over the past month.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
See More
Previous Close:
$4.35
Open:
$4.48
24h Volume:
233.32K
Relative Volume:
0.36
Market Cap:
$3.18M
Revenue:
-
Net Income/Loss:
$-9.60M
P/E Ratio:
-1.4272
EPS:
-3.16
Net Cash Flow:
$-8.96M
1W Performance:
-51.24%
1M Performance:
-52.43%
6M Performance:
-26.31%
1Y Performance:
-40.81%
1-Day Range:
$4.30
$4.70
1-Week Range:
$4.20
$9.25
52-Week Range:
$4.20
$28.60
Artelo Biosciences Inc Stock (ARTL) Company Profile
Name
Artelo Biosciences Inc
Sector
Industry
Phone
858-925-7049
Address
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
4.51 | 5.75M | 0 | -9.60M | -8.96M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Feb-12-21 | Initiated | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Stock (ARTL) Latest News
Price action breakdown for Artelo Biosciences Inc.Rate Cut & Consistent Return Strategy Ideas - Newser
Sentiment analysis tools applied to Artelo Biosciences Inc.July 2025 EndofMonth & Pattern Based Trade Signal System - Newser
Published on: 2025-09-06 13:10:32 - Newser
How to use a screener to detect Artelo Biosciences Inc. breakouts2025 Market Sentiment & Daily Profit Focused Screening - Newser
Artelo Biosciences closes $3 million public offering of common stock By Investing.com - Investing.com Canada
Is Artelo Biosciences Inc. a turnaround story2025 Trading Recap & Fast Momentum Stock Entry Tips - خودرو بانک
Artelo Biosciences' $3.0M Raise and Strategic Implications for Clinical Advancement and Shareholder Value - AInvest
Artelo Biosciences Closes $3 Mln Public Offering Of Common Stock And Pre-Funded Warrants - Nasdaq
Artelo Biosciences Announces Closing of $3.0 Million Public Offe - GuruFocus
Artelo Biosciences closes $3 million public offering of common stock - Investing.com
Artelo Biosciences Closes $3 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Artelo Biosciences Announces Closing of $3.0 Million Public Offering - GlobeNewswire
Artelo Biosciences Completes $3 Million Public Offering - AInvest
Clinical-Stage Biotech Artelo Biosciences Secures $3M Through Public Offering at $4.40 Per Share - Stock Titan
Artelo Biosciences 15min Chart Triggers KDJ Golden Cross, Bullish Marubozu Candle - AInvest
Form 424B5 ARTELO BIOSCIENCES, INC. - StreetInsider
NuCana Achieves Nasdaq Compliance, Anticipates Funding Until 2029 - AInvest
Leading vs lagging indicators on Artelo Biosciences Inc. performanceJuly 2025 Reactions & Safe Capital Growth Tips - Newser
Artelo Biosciences Inc. stock trend outlook and recovery path2025 Key Lessons & Consistent Growth Equity Picks - Newser
Ranking Artelo Biosciences Inc. among high performing stocks via toolsProduct Launch & Real-Time Buy Signal Notifications - Newser
Artelo Biosciences prices $3 million public offering of common stock By Investing.com - Investing.com Canada
Artelo Biosciences Raises $3mln Through Common Stock and Warrant Offering - AInvest
Artelo Biosciences Prices $3 Mln Public Offering Of Common Stock And Warrants - Nasdaq
Artelo Biosciences announces pricing of $3 million public offering - MSN
How to read the order book for Artelo Biosciences Inc.Portfolio Return Report & Low Drawdown Trading Strategies - Newser
Nasdaq Gains Over 100 Points; Science Applications Shares Fall After Q2 Results - Benzinga
Artelo Biosciences Plummets 51%: A Tale of Triumph and Turmoil in Biotech's High-Stakes Arena - AInvest
Artelo Biosciences Plummets 51%: Can Positive Trial Results Salvage Investor Confidence? - AInvest
Artelo Biosciences announces pricing of $3.0 million public offering - MarketScreener
Can Artelo Biosciences Inc. sustain its profitabilityCPI Data & Community Driven Trade Alerts - خودرو بانک
Artelo Biosciences launches public offering of common stock By Investing.com - Investing.com Australia
Artelo Biosciences prices $3 million public offering of common stock - Investing.com
Artelo Biosciences Prices $3 Million Offering; Shares Fall 50% Pre-Bell - MarketScreener
Artelo Biosciences Plunges 28.08% on Public Offering Announcement - AInvest
Artelo Biosciences Announces $3M Public Offering of Common Stock and Warrants. - AInvest
Artelo Biosciences Announces Pricing of $3.0 Million Public Offering - GlobeNewswire
$3 Million Capital Raise: Clinical-Stage Biotech Artelo Prices Public Offering for Cancer & Pain Research - Stock Titan
Artelo Biosciences Launches Public Offering with Undetermined Size and Terms - AInvest
Artelo Biosciences Plunges 14.38% on Public Offering Announcement - AInvest
Custom strategy builders for tracking Artelo Biosciences Inc.July 2025 Opening Moves & Community Consensus Stock Picks - Newser
Building trade automation scripts for Artelo Biosciences Inc.Weekly Stock Summary & Smart Swing Trading Techniques - Newser
What Fibonacci levels say about Artelo Biosciences Inc. reboundTrade Entry Report & Safe Capital Growth Plans - Newser
Will Artelo Biosciences Inc. continue its uptrendAnalyst Upgrade & Free Real-Time Market Sentiment Alerts - Newser
How to interpret RSI for Artelo Biosciences Inc. stockWeekly Profit Report & Safe Entry Point Identification - Newser
Artelo Biosciences reports interim Phase 2 data for cancer cachexia treatment By Investing.com - Investing.com South Africa
Is a relief rally coming for Artelo Biosciences Inc. holdersMarket Sentiment Summary & Long-Term Safe Investment Ideas - Newser
Will Artelo Biosciences Inc. benefit from macro trendsMarket Performance Summary & Technical Confirmation Trade Alerts - Newser
Does Artelo Biosciences Inc. offer margin of safetyJuly 2025 Momentum & Consistent Return Strategy Ideas - khodrobank.com
Artelo Biosciences announces proposed underwritten public offering - MarketScreener
Artelo Biosciences launches public offering of common stock - Investing.com
Artelo Biosciences reports interim Phase 2 data for cancer cachexia treatment - Investing.com
Artelo Biosciences Inc Stock (ARTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):